Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IGH (Immunoglobulin Heavy Locus) • CD22 (CD22 Molecule) • TCF3 (Transcription Factor 3)
|
KMT2A rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • AUTO1/22